Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Avid Bioservices Inc

Is Your Portfolio Healthy? Don't Touch This Stock With a Ten-Foot Pole!

Amidst lingering economic uncertainties, pharma contract development company Avid Bioservices (CDMO) has been flashing red flags with deteriorating financial results in the last reported quarter and bleak prospects. Therefore, I think this fundamentally weak stock might be best avoided. Keep reading.

StockNews.com · Apr 27, 2023

Read How Avid Bioservices Fared In Q4

Read How Avid Bioservices Fared In Q4

Avid Bioservices Inc (NASDAQ:CDMO) reported Q4 FY22 sales of $31.2 million, up 13% Y/Y, beating the consensus of $28.96 million. The growth is attributed to an increase in the scope of in-process and completed manufacturing runs and process development revenues. The company signed multiple new project orders during Q4 totaling approximately $44…

Benzinga · Jun 30, 2022

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

1

Coverage From

People

Kritika SarmahHer

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

inkl

Read news from The Economist, FT, and more,
with one subscription

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play